Was Jim Cramer Right About Pfizer Inc. (PFE)?

We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other stocks that Jim Cramer discusses.

In that older episode, a viewer asked whether it was time to sell or hold shares of Pfizer Inc. (NYSE:PFE), a stock struggling with post-COVID uncertainty and weak pipeline sentiment. Cramer acknowledged the challenges but urged patience, highlighting the company’s acquisition of Seagen:

“I think we’re going to see some results from Seagen — remember they bought Seattle Genetics. You’ve got that yield, they’re paying you to wait. It’s kind of like a CD with maybe some upside.”

He said to be patient with the Seagen deal, but PFE is down -20.52%, showing it was the wrong call.

Pfizer Inc. (NYSE:PFE) is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines across therapeutic areas including oncology, cardiology, and infectious disease.

Cramer hasn’t changed his view on the pharma stock at all. Here’s what he said on May 30:

A medical technician wearing protective gloves and a mask mixing a biopharmaceutical solution.

“Oh, they are. You know something, David, I’m with you. 7% yield. It’s got to be something big coming out of that Seagen acquisition real soon about some hard to beat cancers. I am with Albert Bourla and I am with you. I think we can own the stock of Pfizer.”

Overall, PFE ranks 8th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.